AZ bids for yet another Seroquel use

AstraZeneca is taking its Seroquel-broadening mission further into Europe with an application to market the atypical antipsychotic for generalized anxiety disorder. If European regulators approve the new use, Seroquel would be the first med in its class OK'd for anxiety.

The company says it's basing its application on five Phase III studies encompassing more than 3,500 patients. The data, presented at the American Psychiatric Association confab in May, showed "significantly greater symptom improvements" in the Seroquel patients versus those on placebo, the company said.

AstraZeneca is awaiting an FDA decision on using Seroquel to treat short-term anxiety and for long-term maintenance of the disorder. The company also has an application for major depressive disorder pending, both in the U.S. and in Europe.

- see the AstraZeneca release

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.